Compare
Spero Therapeutics, Inc. vs Kura Oncology, Inc. vs Enanta Pharmaceuticals Inc vs Rockwell Medical, Inc.
| Latest fiscal year | Spero Therapeutics, Inc. SPRO | Kura Oncology, Inc. KURA | Enanta Pharmaceuticals Inc ENTA | Rockwell Medical, Inc. RMTI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-09-30 | 2025-12-31 |
| Revenue | $66.80M | $67.48M | $65.32M | $69.26M |
| Revenue growth (YoY) | +39.2% | +25.2% | -3.4% | -31.8% |
| Gross margin | n/a | n/a | n/a | 16.9% |
| Operating margin | 9.5% | -449.9% | -130.7% | -6.8% |
| Net margin | 12.8% | -412.9% | -125.4% | -7.7% |
| Net income | $8.57M | -$278.67M | -$81.89M | -$5.31M |
| EPS (Diluted) | $0.15 | -$3.18 | -$3.84 | -$0.15 |
| Operating cash flow | -$12.62M | -$64.06M | -$19.27M | -$659.0K |
| Free cash flow | n/a | -$70.70M | -$32.17M | -$1.20M |
| Cash & equivalents | $40.27M | $149.10M | $32.30M | $10.71M |
| Total assets | $68.92M | $738.36M | $280.73M | $57.15M |
| Total liabilities | $9.90M | $564.23M | $216.01M | $20.16M |
| Shareholders' equity | $59.02M | $174.13M | $64.72M | $36.98M |
| Return on year-end equity | 14.5% | -160.0% | -126.5% | -14.4% |
| Shares outstanding | 56.41M | 87.86M | 21.39M | 39.41M |
Revenue, most recent five fiscal years
| Fiscal year | Spero Therapeutics, Inc. | Kura Oncology, Inc. | Enanta Pharmaceuticals Inc | Rockwell Medical, Inc. |
|---|---|---|---|---|
| Latest | $66.80M Ended 2025-12-31 | $67.48M Ended 2025-12-31 | $65.32M Ended 2025-09-30 | $69.26M Ended 2025-12-31 |
| 1 year earlier | $47.98M Ended 2024-12-31 | $53.88M Ended 2024-12-31 | $67.64M Ended 2024-09-30 | $101.49M Ended 2024-12-31 |
| 2 years earlier | $103.78M Ended 2023-12-31 | $0 Ended 2023-12-31 | $79.20M Ended 2023-09-30 | $83.61M Ended 2023-12-31 |
| 3 years earlier | $53.51M Ended 2022-12-31 | n/a | $86.16M Ended 2022-09-30 | $72.81M Ended 2022-12-31 |
| 4 years earlier | $18.26M Ended 2021-12-31 | n/a | $97.07M Ended 2021-09-30 | $61.93M Ended 2021-12-31 |